Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | STAT3 | P40763 | 1/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.54 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.47 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.47 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.46 |
| ▸ | TUBB | P07437 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4791992 | 0.88 | MAP2K4 (0.65) | KDM4ESTAT3HIF1ANR4A2MAP2K4 | |
| SCHEMBL30609861 | 0.88 | MAP2K4 (0.65) | KDM4ESTAT3HIF1ANR4A2MAP2K4 | |
| SCHEMBL4793050 | 0.83 | KDM4E (0.65) | KDM4ESTAT3HIF1ANR4A2MAP2K4 | |
| SCHEMBL173308 | 0.83 | KDM4E (0.65) | KDM4ESTAT3HIF1ACDC7DYRK1A | |
| SCHEMBL17324736 | 0.83 | ROCK1 (0.47) | MAP2K4DYRK1AROCK1PRKAG1PRKAA1 | |
| SCHEMBL11160240 | 0.82 | KMT2A (0.50) | KDM4ESTAT3HIF1ANR4A2MAP2K4 | |
| SCHEMBL11169705 | 0.82 | KMT2A (0.50) | KDM4ESTAT3HIF1ANR4A2MAP2K4 | |
| SCHEMBL27814101 | 0.82 | ROCK1 (0.49) | MAP2K4DYRK1AROCK1PRKAG1PRKAA1 | |
| SCHEMBL4794844 | 0.82 | KDM4E (0.63) | KDM4ESTAT3HIF1ANR4A2CDC7 | |
| SCHEMBL1141823 | 0.82 | KDM4E (0.63) | KDM4ESTAT3HIF1ACDC7DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-09-19 | — | — | US | disclosed |
| CN-112805282-A | Indazole-carboxamide derivatives and uses thereof | 广东东阳光药业有限公司 | 2021-05-14 | — | — | CN | disclosed |
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-24 | — | — | US | disclosed |
| CN-106061480-B | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2020-02-28 | — | — | CN | disclosed |
| EP-3089746-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2016-11-09 | — | — | EP | disclosed |
| EP-2565192-B9 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-9156827-B2 | Anticancer agent | THE UNIVERSITY OF TOKYO (JP) | 2015-10-13 | — | — | US | disclosed |
| EP-2565192-B1 | ANTICANCER AGENT | UNIV TOKYO (JP) | 2015-08-12 | — | — | EP | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| US-20130102776-A1 | ANTICANCER AGENT | RIKEN (JP) | 2013-04-25 | — | — | US | disclosed |
| EP-2565192-A1 | ANTICANCER AGENT | The University of Tokyo (JP) | 2013-03-06 | — | — | EP | disclosed |
| EP-1937647-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036727-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| WO-2007036727-A1 | CONDENSED PYRAZOLE DERIVATIVES AS PPAR AGONISTS II | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299285-A1 | CARBOXYLIC ACID, ACYL SULFONAMIDE AND ACYL SULFAMIDE-DERIVATIZED BICYCLIC AZA-HETEROAROMATICS AS SELECTIVE MCL-1 INHIBITORS AND AS DUAL MCL-1/BCL-2 INHIBITORS | MCL1, BCLAF1, BCL2A1 | KDM4E 1872/4885STAT3 2089/4885HIF1A 1796/4885 |
| US-11760752-B2 | Carboxylic acid, acyl sulfonamide and acyl sulfamide-derivatized bicyclic aza-heteroaromatics as selective Mcl-1 inhibitors and as dual Mcl-1/Bcl-2 inhibitors | MCL1, BCLAF1, BCL2A1 | KDM4E 1872/4885STAT3 2089/4885HIF1A 1796/4885 |
| US-20130102776-A1 | ANTICANCER AGENT | PIM1, PIM3, PIM2 | KDM4E 540/4885STAT3 532/4885HIF1A 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.